6 key clin­i­cal tri­al trends that we should em­brace and build on

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

When peni­cillin was dis­cov­ered in 1928 by Alexan­der Flem­ing, the av­er­age clin­i­cal tri­al time was 12 years. In 2021, the av­er­age in­dus­try tri­al time is 10 years, an im­prove­ment of on­ly 2 years. In al­most a cen­tu­ry, there have been no ad­vance­ments that have de­liv­ered a sub­stan­tial change to how clin­i­cal tri­als are con­duct­ed.

While the Covid-19 pan­dem­ic it­self had a dev­as­tat­ing im­pact on tri­als around the world, the dis­rup­tion it caused al­so car­ries with it the chance for in­no­va­tion. The ur­gency and ac­cel­er­a­tion to adopt new ways of work­ing caused by the pan­dem­ic is al­so an op­por­tu­ni­ty. By main­tain­ing the in­no­va­tion mind­set that ini­tial­ly came from ne­ces­si­ty, the in­dus­try can dri­ve durable, sus­tain­able in­no­va­tion with the po­ten­tial to trans­form the clin­i­cal de­vel­op­ment mod­el. Here are 6 key trends that we should em­brace and build on mov­ing for­ward.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN